Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Video

Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

Sham Mailankody, MBBS, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

There are many studies examining BCMA CAR T-cell therapy in various stages of clinical development. A recent publication in the New England Journal of Medicine showed that bb2121, a BCMA CAR T-cell product that was used for treatment of patients with relapsed/refractory multiple myeloma, is associated with high response rates, explains Mailankody.

The overall response rate was 85% and the complete response rate was 45%, which is unprecedented in this patient population. However, relapses are common and, in this study, the median progression-free survival was 11.7 months, showing that there is room for improvement, Mailankody concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.